In phase I results from China published in the Journal of Clinical Oncology,
oral pyrotinib (HTI-1001) was well-tolerated and showed antitumor activity in women with HER2-positive breast cancer.
“We need additional studies to evaluate this new compound and questions need to be answered on what chemotherapy regimen it will be combined with and whether it is less toxic or more efficacious than our current anti-HER2 medications.”
Ma F, Li Q, Chen S, et al. Phase I study and biomarker analysis of pyrotinib, a novel irreversible pan-erbb receptor tyrosine kinase inhibitor, in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer [published online May 12, 2017]. J Clin Oncol. doi: 10.1200/JCO.2016.69.6179.
... to read the full story